Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Adhikary, Gautam  [Clear All Filters]
Journal Article
Eckert RL, Fisher ML, Grun D, Adhikary G, Xu W, Kerr C. Transglutaminase is a tumor cell and cancer stem cell survival factor. Mol Carcinog. 2015.
Chen X, Adhikary G, Newland JJ, Xu W, Keillor JW, Weber DJ, Eckert RL. Transglutaminase 2 binds to the CD44v6 cytoplasmic domain to stimulate CD44v6/ERK1/2 signaling and maintain an aggressive cancer phenotype. Mol Cancer Res. 2023.
Rorke EA, Adhikary G, Young CA, Roop DR, Eckert RL. Suppressing AP1 Factor Signaling in Suprabasal Epidermis Produces A Keratoderma Phenotype. J Invest Dermatol. 2014.
Rorke EA, Adhikary G, Szmacinski H, Lakowicz JR, Weber DJ, Godoy-Ruiz R, Puranik P, Keillor JW, Gates EWJ, Eckert RL. Sulforaphane covalently interacts with the transglutaminase 2 cancer maintenance protein to alter its structure and suppress its activity. Mol Carcinog. 2021.
McNeil NMR, Gates EWJ, Firoozi N, Cundy NJ, Leccese J, Eisinga S, Tyndall JDA, Adhikary G, Eckert RL, Keillor JW. Structure-activity relationships of N-terminal variants of peptidomimetic tissue transglutaminase inhibitors. Eur J Med Chem. 2022;232:114172.
Kandasamy S, Adhikary G, Rorke EA, Friedberg JS, Mickle MKB, H Alexander R, Eckert RL. Correction: The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype. Mol Cancer Res. 2023;21(9):991.